Tenaciously Pursuing Approval for Novel Gene Therapy
When an emerging U.S.-based pharmaceutical sponsor initiated its Phase I clinical trial in 2007 for a novel gene therapy for subjects with a rare inherited form of vision loss, it faced many obstacles. Gene therapy was less than 20 years old, and several years earlier the unfortunate death of a clinical trial subject had spiked concerns about the treatment. Nevertheless, the sponsor pushed forward on its ground-breaking research.
While preparing an interim data report for the U.S. Food and Drug Administration (FDA) in 2010, the original CRO fell short, and the sponsor critically needed a replacement able to hit the ground running. The sponsor knew Westat’s work having previously contracted with us for statistical support and asked us to step in. We took on the project management, site monitoring, pharmacovigilance, data management, and SAS programming support for the Phase I study already in progress, as well as the planned Phase II mobility validation and natural history studies, and the Phase III pivotal trial.
Stepping in With an Immediate and Assured Start
Our agile and experienced team promptly took action by meeting with the site staff to understand the complex processes for ophthalmologic testing and data reporting. We uncovered numerous data discrepancies in the original interim data report and implemented processes to standardize the testing procedures. We also trained the site staff on best practices for source documentation. This resulted in a solid foundation for the integrity of the data, ensuring our sponsor could count on an optimally designed and statistically sound study.
Providing Trusted, Ongoing Project Support
One of the sponsor’s requirements was a dedicated project director who would oversee all of the studies and serve as an integral part of the team. Westat CLS delivered with an experienced project manager and support team to oversee the projects for the life of the program. In fact, our project management was so trusted that when members of the sponsor organization founded their own company, they continued to rely on us to support their number-one priority program.
Securing FDA Approval
In 2017, the FDA advisory panel unanimously recommended the approval of the sponsor’s gene therapy product. Westat was instrumental in preparing for the advisory panel meeting; we developed tables, graphs, slides and proposed answers to a multitude of questions that could be posed by the panel. Later that year, the FDA approved the novel gene therapy to treat children and adult patients with the inherited condition.
Westat CLS was an assured, experienced, and reliable partner to our sponsor from the early and pivotal phases through the Biologics License Application and Advisory Committee Meeting with the FDA.
Featured Project Highlights
Launching an Oncology Trial in the Emerging COVID-19 Pandemic
When a small international company approached Westat in 2020 to conduct a phase I solid tumor study, the World Health Organization had just declared the COVID-19 outbreak as a global pandemic. Aggressive actions to contain the spread of COVID-19 were implemented. People were asked to shelter at home, access to all but the most critical medical procedures was restricted, and hospitals implemented strict policies on entrance and admissions. The challenge was to navigate this environment while simultaneously kicking off a rigorous study protocol.
Expediting an Urgent Sub-study for COVID-19 Treatment
During the global pandemic of 2020, Westat pivoted with urgency to help leverage existing infrastructure from an ongoing influenza study toward a sub-study for a COVID-19 treatment. Despite the challenges posed by the pandemic, our experts successfully implemented remote site monitoring and new safety procedures.
Rescuing a Fledgling Parainfluenza Study and Seeing It Through
Westat rose to the challenge of staffing and transitioning a troubled Phase III study and accomplished a smooth transfer in record time. We leveraged our network of in-country partners to deliver a successful study across 19 sites in six countries and commenced approval submissions within just three months.